(0)サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747731

実世界のデータの世界市場

Real World Data

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
実世界のデータの世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

実世界のデータの世界市場は2030年までに54億米ドルに到達

2024年に22億米ドルと推定される実世界のデータの世界市場は、2024年から2030年にかけてCAGR 15.9%で成長し、2030年には54億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである「サービスコンポーネント」は、CAGR 17.7%を記録し、分析期間終了時には37億米ドルに達すると予測されます。データセットコンポーネント分野の成長率は、分析期間中CAGR 12.5%と推定されます。

米国市場は5億9,050万米ドルと推定、中国はCAGR14.9％で成長予測

米国の実世界のデータ市場は、2024年に5億9,050万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR14.9%で推移し、2030年までに8億3,540万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.8％と13.5％と予測されています。欧州では、ドイツがCAGR 11.4%で成長すると予測されています。

世界の「実世界のデータ」市場- 主要動向と促進要因のまとめ

実世界のデータはエビデンスに基づく意思決定の未来を再構築するか？

実世界のデータ（RWD）はヘルスケアイノベーションの礎石となりつつあり、管理された臨床試験から患者の実体験から引き出されたエビデンスへとパラダイムをシフトしています。電子カルテ（EHR）、保険請求、患者登録、ウェアラブル、モバイルヘルスアプリから得られるRWDは、多様な集団における治療効果、安全性、アドヒアランス、転帰に関する洞察を提供します。これにより、規制当局、支払者、製薬会社は、管理された環境外で治療がどのように行われるかを理解することができ、適応性のある臨床試験、ファーマコビジランス、価値に基づく償還モデルを支援することができます。公衆衛生では、RWDは政策決定に情報を提供し、リアルタイムで病気の進行を追跡します。ヘルスケアシステムが個別化されたデータ主導のケアを推進する中、RWDは患者の行動を実用的な臨床的洞察と結びつける戦略的資産として台頭してきています。

RWDの可能性を最大限に引き出すテクノロジーとは？

健康データの爆発的な増加とデータ分析の進歩は、実世界のデータ活用の新たなフロンティアを解き放ちつつあります。クラウドコンピューティング、ビッグデータプラットフォーム、AIアルゴリズムは、膨大な異種データセットの取り込み、調和、リアルタイム分析を可能にしています。自然言語処理（NLP）は、クリニカルノートや非構造化EHRデータから構造化された洞察を抽出します。HL7 FHIRのような相互運用性フレームワークは、システムや利害関係者間でのデータ共有を改善しています。ブロックチェーンは、データの出所、セキュリティ、患者の同意を確保するために検討されています。これらの技術は、RWDを受動的な記録から、医薬品開発、集団健康戦略、個別化された治療経路を促進する動的なリソースへと変えつつあります。データエコシステムが成熟するにつれて、RWDの品質、信頼性、規制当局の受容性も向上しています。

ヘルスケア・エコシステム全体の利害関係者はどのようにRWDを受け入れているのか？

製薬会社は、臨床試験デザインや施設選定から市販後調査やラベル拡大まで、医薬品ライフサイクルの全段階にRWDを組み込んでいます。FDAやEMAのような規制当局は、承認をサポートし、実世界の集団における安全性を監視するために、ますますRWDに依存しています。支払者は、費用対効果を評価し、保険適用を決定するためにRWDを使用しています。ヘルスケアプロバイダーは、RWDアナリティクスを適用して、ケアコーディネーションを改善し、再入院を減らし、治療プロトコルを最適化しています。患者も重要な利害関係者となりつつあり、アプリやウェアラブルデバイスを通じてデータを提供し、透明性とコントロールを要求しています。RWDをめぐる利害関係者の関心の収束は、パートナーシップ、データコンソーシアム、イノベーションハブを育成し、健康データを健康への影響に変換することを加速させています。

世界的に実世界のデータ市場の成長を加速させているものは？

実世界のデータ市場の成長は、ヘルスデータインフラストラクチャの進歩、規制当局のサポート、個別化された価値ベースのケアに対するエンドユーザーの需要によってもたらされます。技術的には、分析ツールの改善、クラウドの拡張性、相互運用性の標準化により、膨大で多様なデータセットから実用的な洞察を得ることが可能になっています。エンドユーザーの視点に立つと、バイオファーマ、支払者、医療システムはRWDを活用して効率化を推進し、アウトカムを最適化し、進化するケアへの期待に応えています。デジタルヘルスツール、ウェアラブル、患者エンゲージメント・プラットフォームの利用が増加し、分析のためのより豊富なデータセットが生成されています。意思決定や政策策定においてRWDを支援する規制上の取り組みも、市場の信頼性を高めています。世界のヘルスケアシステムが量から価値へと移行する中、実世界のエビデンスから有意義な考察を導き出す能力は、競争上の重要な差別化要因になりつつあります。

セグメント

コンポーネント（サービス、データセット）;用途（医薬品開発・承認、市場参入・償還／調査対象決定、市販後調査、臨床研究、その他の用途）;最終用途（製薬・医療機器企業、医療費負担者、ヘルスケアプロバイダー、政府機関、その他の最終用途）

調査対象企業の例（全42件）

  • Aetion, Inc.
  • Atropos Health
  • BEKHealth
  • Cerner Corporation
  • Clarify Health Solutions
  • ConcertAI
  • Datavant
  • Evidera, Inc.
  • Flatiron Health, Inc.
  • HealthVerity
  • IBM Corporation
  • ICON plc
  • IQVIA Holdings Inc.
  • K2view
  • Merative
  • Mount Sinai Health System
  • Optum, Inc.
  • Palantir Technologies Inc.
  • PAREXEL International Corporation
  • SAS Institute Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP35640

Global Real World Data Market to Reach US$5.4 Billion by 2030

The global market for Real World Data estimated at US$2.2 Billion in the year 2024, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 15.9% over the analysis period 2024-2030. Services Component, one of the segments analyzed in the report, is expected to record a 17.7% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Datasets Component segment is estimated at 12.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$590.5 Million While China is Forecast to Grow at 14.9% CAGR

The Real World Data market in the U.S. is estimated at US$590.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$835.4 Million by the year 2030 trailing a CAGR of 14.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.8% and 13.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.4% CAGR.

Global "Real World Data" Market - Key Trends & Drivers Summarized

Is Real World Data Reshaping The Future Of Evidence-Based Decision Making?

Real World Data (RWD) is becoming a cornerstone of healthcare innovation, shifting the paradigm from controlled clinical trials to evidence drawn from real-life patient experiences. Sourced from electronic health records (EHRs), insurance claims, patient registries, wearables, and mobile health apps, RWD provides insights into treatment efficacy, safety, adherence, and outcomes across diverse populations. It allows regulators, payers, and pharmaceutical companies to understand how therapies perform outside controlled environments, supporting adaptive clinical trials, pharmacovigilance, and value-based reimbursement models. In public health, RWD informs policy decisions and tracks disease progression in real-time. As healthcare systems push for personalized, data-driven care, RWD is emerging as a strategic asset that links patient behavior with actionable clinical insights.

What Technologies Are Unlocking The Full Potential Of RWD?

The explosion of health data and advances in data analytics are unlocking new frontiers for Real World Data utilization. Cloud computing, big data platforms, and AI algorithms are enabling the ingestion, harmonization, and real-time analysis of massive, heterogeneous datasets. Natural language processing (NLP) is extracting structured insights from clinical notes and unstructured EHR data. Interoperability frameworks like HL7 FHIR are improving data sharing across systems and stakeholders. Blockchain is being explored to ensure data provenance, security, and patient consent. These technologies are transforming RWD from passive records into dynamic resources that fuel drug development, population health strategies, and personalized treatment pathways. As data ecosystems mature, the quality, reliability, and regulatory acceptance of RWD are also improving.

How Are Stakeholders Across The Healthcare Ecosystem Embracing RWD?

Pharmaceutical companies are integrating RWD into all stages of the drug lifecycle-from trial design and site selection to post-market surveillance and label expansion. Regulators like the FDA and EMA are increasingly relying on RWD to support approvals and monitor safety in real-world populations. Payers are using RWD to assess cost-effectiveness and inform coverage decisions. Healthcare providers are applying RWD analytics to improve care coordination, reduce readmissions, and optimize treatment protocols. Patients are also becoming key stakeholders, contributing data through apps and wearable devices while demanding transparency and control. The convergence of stakeholder interests around RWD is fostering partnerships, data consortiums, and innovation hubs that accelerate the transformation of health data into health impact.

What’s Accelerating Growth In The Real World Data Market Globally?

The growth in the Real World Data market is driven by advancements in health data infrastructure, regulatory support, and end-user demand for personalized, value-based care. Technologically, improved analytics tools, cloud scalability, and interoperability standards are enabling actionable insights from vast and diverse datasets. From an end-use perspective, biopharma, payers, and health systems are leveraging RWD to drive efficiency, optimize outcomes, and meet evolving care expectations. Increased use of digital health tools, wearables, and patient engagement platforms is generating richer datasets for analysis. Regulatory initiatives supporting RWD in decision-making and policy formulation are also boosting market credibility. As global healthcare systems transition from volume to value, the ability to derive meaningful insights from real-world evidence is becoming a key competitive differentiator.

SCOPE OF STUDY:

The report analyzes the Real World Data market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Services, Datasets); Application (Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research, Other Applications); End-Use (Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers, Government Agencies, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Aetion, Inc.
  • Atropos Health
  • BEKHealth
  • Cerner Corporation
  • Clarify Health Solutions
  • ConcertAI
  • Datavant
  • Evidera, Inc.
  • Flatiron Health, Inc.
  • HealthVerity
  • IBM Corporation
  • ICON plc
  • IQVIA Holdings Inc.
  • K2view
  • Merative
  • Mount Sinai Health System
  • Optum, Inc.
  • Palantir Technologies Inc.
  • PAREXEL International Corporation
  • SAS Institute Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Real World Data - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Accelerated Shift Toward Evidence-Based Healthcare Models Spurs Use of Real World Data
    • Increased Regulatory Acceptance of RWD in Drug Approvals and Label Expansions Drives Market Relevance
    • Rising Use of EHR, Claims, and Patient-Reported Outcomes Data Expands Data Variety
    • Growth in Value-Based Care and Health Economics Research Strengthens Demand for Real-World Evidence
    • AI and Advanced Analytics Integration Enhances Data Utility in Clinical and Commercial Strategy
    • Collaborations Between Pharma, Payers, and Tech Firms Propel RWD Platform Development
    • Decentralized Clinical Trials and Virtual Health Models Expand Demand for Real-Time Patient Data
    • Regulatory Pressure for Post-Market Surveillance and Pharmacovigilance Supports Adoption
    • Privacy Concerns and Data Governance Requirements Present Compliance Challenges
    • Global Expansion of Health Data Infrastructure Opens Regional Growth Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Real World Data Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Real World Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Real World Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Datasets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Datasets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Healthcare Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Healthcare Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Government Agencies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Government Agencies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical & Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Pharmaceutical & Medical Device Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Healthcare Payers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Healthcare Payers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Drug Development & Approvals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Drug Development & Approvals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Market Access & Reimbursement / Coverage Decisions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Market Access & Reimbursement / Coverage Decisions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Post-Market Surveillance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Post-Market Surveillance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • JAPAN
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • CHINA
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 46: China Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • EUROPE
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Real World Data by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Real World Data by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • FRANCE
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 60: France Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • GERMANY
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 78: UK Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030

IV. COMPETITION